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Background: A relevant burden of defective HIV-1 genomes populates PBMCs from HIV-1 infected patients,
especially during HAART treatment. These viral genomes, although unable to codify for infectious viral particles, can
express viral proteins which may affect functions of host cells as well as bystander ones. Cells expressing defective
HIV-1 have a lifespan longer than that of cells producing infectious particles. Hence, their interaction with other
cell types, including resting lymphocytes, is expected to occur frequently in tissues where HIV actively replicates.
We investigated the effects of the expression of a prototype of functionally defective HIV-1 on bystander, unstimulated
CD4+ T lymphocytes.
Results: We observed that unstimulated human primary CD4+ T lymphocytes were activated and became permissive
for HIV-1 replication when co-cultivated with cells expressing a functionally defective HIV-1 (F12/Hut-78 cells). This effect
depended on the presence in F12/Hut-78 supernatants of nanovesicles we identified as exosomes. By inspecting the
underlying mechanism, we found that ADAM17, i.e., a disintegrin and metalloprotease converting pro-TNF-α in its
mature form, associated with exosomes from F12/Hut-78 cells, and played a key role in the HIV-1 replication in
unstimulated CD4+ T lymphocytes. In fact, the treatment with an inhibitor of ADAM17 abolished both activation and
HIV-1 replication in unstimulated CD4+ T lymphocytes. TNF-α appeared to be the downstream effector of ADAM17
since the treatment of unstimulated lymphocytes with antibodies against TNF-α or its receptors blocked the HIV-1
replication. Finally, we found that the expression of NefF12 in exosome-producing cells was sufficient to induce the
susceptibility to HIV-1 infection in unstimulated CD4+ T lymphocytes.
Conclusions: Exosomes from cells expressing a functionally defective mutant can induce cell activation and HIV-1
susceptibility in unstimulated CD4+ T lymphocytes. This evidence highlights the relevance for AIDS pathogenesis of the
expression of viral products from defective HIV-1 genomes.
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The high frequency of mutations occurring in HIV-1 ret-
rotranscription can lead to the production of defective
HIV-1 genomes. They can persist in peripheral blood
mononuclear cells (PBMCs) of HIV-1 infected patients
since host cells are expected to have a lifetime longer
than that of cells infected by replication-competent qua-
sispecies. First evidences about the significant presence
in vivo of defective HIV-1 genomes came from the* Correspondence: Maurizio.federico@iss.it
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unless otherwise stated.observation that the number of PBMCs containing
HIV-1 DNA greatly exceeds that of cells expressing in-
fectious HIV-1 [1,2]. Later, 46% of HIV-1 genomes de-
tected in PBMCs from 10 infected patients was found
deleted, while PBMCs from 3 patients harbored only de-
leted or rearranged HIV-1 genomes [3]. Sequence analysis
of the HIV-1 RT gene in PBMCs and rectal tissue of highly
active anti-retroviral therapy (HAART)-treated patients
revealed a great number of stop codons in all samples ana-
lyzed [4]. More recently, the analysis of 213 proviral clones
from treated patients demonstrated the presence of 88.3%
of genomes with identifiable defects [5].ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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http://www.retrovirology.com/content/11/1/46Of major importance, mutations do not necessarily ham-
per the expression of defective HIV-1 genomes. Accord-
ingly, defects in basically all HIV-1 genes except tat were
identified in genomes of HIV-1 isolated from plasma of
HAART-treated patients [6-10]. At least part of these mu-
tated viral genomes are expected to integrate in host cell
DNA thereby expressing defective HIV-1. Thus, the pres-
ence in HIV-1 infected patients, especially those treated by
HAART, of defective but transcriptionally active HIV-1 ge-
nomes can be relevant, and investigating their role in the
development of the disease would be of interest. We looked
at the effects of the expression of a prototype of function-
ally defective HIV-1 (i.e., F12/HIV-1) [11] on bystander un-
stimulated CD4+ T lymphocytes. This system can mirror
the events occurring in vivo upon interaction of resting
lymphocytes with cells harboring defective HIV-1 genomes
expressing either fully or partially functional viral products.
The Hut-78 cells chronically infected with the non-
producer F12/HIV-1 strain (referred to as F12/Hut-78 cells)
were obtained by cloning cells infected by supernatants of
PBMCs from an HIV-1 infected patient [11]. Cells express-
ing such HIV-1 mutant do not release infectious viral parti-
cles, meanwhile expressing a complete viral protein pattern
comprising a truncated Vpr, an uncleaved Env gp160, and a
mutated Nef (Table 1) [12]. In the present study, we pro-
vide evidence that exosomes released by F12/Hut-78 cells
can influence the cell activation state of bystander, unstimu-
lated CD4+ T lymphocytes.
Exosomes are nanovesicles released by all cell types.
They are lipid bilayer vesicles of 50–100 nanometers
which form intracellularly upon inward invagination of
endosome membranes [16]. This event leads to the for-
mation of intraluminal vesicles which then become partTable 1 Proteome of F12/HIV-1a
Viral gene Amino acid substitutions
gag p17: 1
p24: 6
p15: 3
pol Pro: 3
RT: 10
Endo: 2
env gp120: 4
gp41: 2
nef 3
tat 0
rev 0
vif 14
vpr 3
vpu 0
aThe F12/HIV-1 amino acid sequence was compared to a consensus sequence obtaine
have been found in the LTRs, TAR, and RRE HIV-1 regulatory sequences.of multivesicular bodies. Subsequently, they can undergo to
lysosomal degradation or, alternatively, be released into
extracellular space upon fusion of multivesicular bodies
with plasma membrane. Exosomes can be released also
through direct extrusion of plasma membrane [17]. Current
protocols of purification and marker analysis cannot dis-
criminate between endosome-produced nanovesicles and
vesicles with similar size but originating from cell mem-
branes. For the sake of clarity, cell-produced nanovesicles
are here defined exosomes irrespectively to their origin.
It is now accepted that exosomes are part of the inter-
cellular communication network while they were origin-
ally thought to secrete only waste cell material [18].
Exosomes incorporate messenger RNAs, microRNAs,
and proteins which are functional in target cells [19].
Exosomes from HIV-1 infected cells incorporate Gag
[20] and Nef HIV-1 proteins [21,22]. HIV-1 Gag mole-
cules associate with exosomes by virtue of their higher-
order oligomerization, while Nef is incorporated in exo-
somes upon anchoring into lipid raft microdomains
through its N-terminal myristoylation and a stretch of
basic amino acid residing in its alpha-helix 1.
Here, we demonstrate that the cell activation induced by
exosomes from F12/Hut-78 cells in unstimulated human
primary CD4+ T lymphocytes couples with HIV-1 replica-
tion. These effects relied on the expression of NefF12.
Results
Unstimulated CD4+ T lymphocytes become susceptible to
HIV-1 infection when co-cultivated with cells expressing a
defective HIV-1 strain
We looked at possible effects of the expression of defective
HIV-1 on bystander unstimulated CD4+ T lymphocytes byViral protein product
Inefficient cleavage of the p55 precursor [12,13]
Apparently intact [12]
No cleavage of the gp160 precursor [11,12]
Defects in trafficking and signaling functions [13,14]
Functional [12]
Functional [12]
Functionally defective [12,15]
Premature stop codon at aa 76 [12]
Apparently intact [12]
d with multiple alignments of 5 type B HIV-1 isolates. No nucleotide substitutions
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http://www.retrovirology.com/content/11/1/46setting up trans-well co-cultures of F12/Hut-78 cells with
unstimulated CD4+ T lymphocytes isolated from healthy
donors. F12/Hut-78 cells or, as control, parental uninfected
Hut-78 cells were put in the upper chamber of a 0.4 μm
trans-well plate where unstimulated CD4+ T lymphocytes
were seeded in the bottom chamber. After overnight co-
cultivation, unstimulated CD4+ T lymphocytes were recov-
ered from trans-well plates and infected with HIV-1 in the
presence or not of azidothymidine (AZT). Three days later,
HIV-1 replication in unstimulated cells was evaluated by
FACS analysis for the presence of intracytoplasmic HIV-1
Gag-related products. HIV-1 replicated in unstimulated
CD4+ T lymphocytes from co-cultures with F12/Hut-78
cells but not parental ones (Figure 1A). The HIV-1 replica-
tion did not occur also in CD4+ T lymphocytes from co-
cultures carried out in the presence of AZT (Figure 1A),
thus ensuring that what we detected was consequence of
authentic HIV-1 infection.
Considering that HIV-1 replication in lymphocytes
needs cell activation, we hypothesized that the expres-
sion of the defective HIV-1 generates a signal leading to
lymphocyte activation. To identify the nature of such a
signal, we repeated the co-culture experiments in the
presence of a number of drugs or antibodies. Among the
drugs we tested, HIV-1 replication in bystander cells was
successfully blocked by 1 μΜ of both GW4869 and Spir-
oepoxide (Figure 1B), i.e., two structurally unrelated in-
hibitors of neutral sphingomyelinase blocking exosome
release [23-28]. This result prompted us to focus on exo-
somes as possible effectors of the induction of HIV-1
susceptibility in unstimulated CD4+ T lymphocytes.
Characterization of exosomes from F12/Hut-78 cells
Exosomes from F12/Hut-78 cells were isolated by differ-
ential centrifugations and then purified by 6-18% gradients
of iodixanol. As control, the same procedure was applied
to supernatants from D10/Hut-78 cells, i.e., a cell line
chronically infected with a producer HIV-1 strain [11].
Gradient fractions were assayed for the activity of acetyl-
cholinesterase (AchE, a marker of exosomes) [29], and the
presence of HIV-1 Gag products (Figure 2A). As previ-
ously described [30], 6-18% iodixanol gradients concen-
trated exosomes in fractions 5–8. Here, Gag products also
were detectable (Figure 2A), likely consequence of their
association with exosomes [20]. Conversely, in denser
fractions, where viral particles are expected to float, Gag
products remained undetectable in gradients loaded with
nanovesicles from F12/Hut-78 cells, while they massively
accumulated in gradients with nanovesicles from D10/
Hut-78 cells. Therefore, supernatants from F12/Hut-78
cells appeared to be free of viral particles. Hence, still pos-
sible residual viral particles were expected to only minim-
ally contaminate the exosome preparations from F12/Hut-
78 cells obtained through differential centrifugations.Nanovesicles from F12/Hut-78 cells were formally
identified as exosomes by FACS analysis demonstrating
the presence of both monosialotetrahexosylganglioside
(GM1) [31,32], using FITC-conjugated cholera toxin
fraction B (CTX-B), and CD63 (Figure 2B). In addition,
western blot analysis revealed that, consistently with
what previously described for exosomes from Gag- [20]
or Nef-expressing cells [21,22], both HIV-1 CAp24 and
Nef proteins associate with exosomes from F12/Hut-78
cells (Figure 2C).
Primary unstimulated CD4+ T lymphocytes release both
IL-2 and TNF-α in response to the treatment with exosomes
from F12/Hut-78 cells
HIV-1 replication in quiescent CD4+ T lymphocytes re-
quires cell activation which associates with the release of
interleukin (IL)-2 and tumor necrosis factor (TNF)α. We
asked whether unstimulated CD4+ T lymphocytes release
IL-2 and TNF-α in response to the treatment with exo-
somes from F12/Hut-78 cells. Human unstimulated CD4+
T lymphocytes were challenged with equal amounts of
exosomes derived from F12/Hut-78 cells or, as control,
uninfected Hut-78 cells. Exosomes were quantified in
terms of the activity of AchE as detailed in the Material
and Methods section. We assessed the number of IL-2
producing cells by ELISPOT assay 48 hours after exosome
challenge, and the TNF-α release by ELISA on supernatants
harvested at different hours after challenge. We found that
60 μU of exosomes from F12/Hut-78 cells applied on 105
unstimulated CD4+ T lymphocytes cells generated a num-
ber of cells producing IL-2 significantly increased compared
to untreated cells or cells treated with exosomes from par-
ental Hut-78 cells (Figure 3A). Consistently, higher levels
of TNF-α were detected when unstimulated CD4+ T lym-
phocytes were treated with scaled amounts (i.e., from 15
to 60 μU/105 cells) of exosomes from F12/Hut-78 cells
than from parental ones (Figure 3B). The TNF-α release
peaked at 6 hours post challenge, and returned to control
levels 16 hours after challenge (data not shown). No TNF-
α was detected in the exosome preparations we used for
the challenges (not shown).
These data implied that the treatment of unstimulated
CD4+ T lymphocytes with exosomes from F12/Hut-78
cells leads to cell activation.
The treatment with exosomes from F12/Hut-78 cells
renders unstimulated CD4+ T lymphocytes susceptible to
HIV-1 replication
Next, we investigated whether the cellular activation in-
duced by exosomes released from F12/Hut-78 cells couples
with HIV-1 replication. As previously described [33], timing
of quiescent CD4+ T lymphocyte activation strongly in-
fluences viral replication. Thus, exosomes were added
to unstimulated CD4+ T lymphocytes either: i) six hours
020
10
Nil Nil AZT
%
 H
IV
-1
+
ce
lls
: f
ol
d 
in
cr
ea
se
 
Hut-78 F12/Hut-78
Nil AZT
PHA
CD4+ T 
lymphocytes
+Hut-78 
HIV-1 HIV-1+AZT
SS
C
HIV-1 CAp24
1.1 1.2
CD4+ T 
lymphocytes
CD4+ T 
lymphocytes
+F12/Hut-78 
HIV-1 +AZT
1.3
*
HIV-1 HIV-1+PHA
0.8 15.2<0.1
MockA B
14.8
HIV-1
0
20
10
Nil Nil
%
 H
IV
-1
+
ce
lls
: f
ol
d 
in
cr
ea
se
 
Hut-78 F12/Hut-78
GW/Spx Nil GW/Spx
PHA
Nil GW/Spx
*
α
Figure 1 Exosome-dependent HIV-1 replication in unstimulated CD4+ T lymphocytes after co-cultivation with Hut-78/F12 cells. A. HIV-1
replicates in unstimulated CD4+ T lymphocytes co-cultured in trans-well plates with F12/Hut-78 cells. F12/Hut-78 cells or parental Hut-78 cells
were put in the upper chamber of trans-well plates where unstimulated CD4+ T lymphocytes were seeded in the bottom chamber. After overnight
co-culture, unstimulated CD4+ T lymphocytes were recovered and infected by a T-tropic HIV-1 strain in the presence or not of AZT. As control,
unstimulated and PHA-treated CD4+ T lymphocytes were infected by HIV-1 or left untreated (Mock). Three days later, the lymphocyte cultures
were analyzed by FACS for the expression of HIV-1 Gag-related products. In the upper displays, shown are the dot-plots of FACS analysis from a
representative experiment. Percentages of HIV-1 Gag positive cells are indicated in each plot. In the bottom, the fold increases of the percentages of
HIV-1 CAp24-positive cells compared to cells treated with HIV-1 alone are presented. Shown are the mean of fold increases + SD as calculated from
three independent experiments with duplicates. *p < 0.05. B. Effects of the inhibitors of exosome release on the HIV-1 susceptibility of unstimulated
CD4+ T lymphocytes co-cultured with F12/Hut-78 cells. Trans-well co-cultures were run as described for panel A, however in the presence or not of
the inhibitors of exosome release GW4869 and Spiroepoxide. After overnight co-culture, the unstimulated CD4+ T lymphocyte cultures and, as control,
PHA-activated lymphocytes treated or not with the inhibitors of exosome release were washed and infected by HIV-1. Three days later, the cell cultures
were analyzed by FACS for the expression of HIV-1 Gag-related products. The fold increases of the percentages of HIV-1 CAp24-positive cells compared
to cultures treated with HIV-1 alone are presented. Shown are the mean of fold increases + SD as calculated from three independent experiments with
duplicates. *p < 0.05.
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http://www.retrovirology.com/content/11/1/46before infection with the T-tropic NL4-3 HIV-1 strain; ii)
together with HIV-1, and iii) six hours after HIV-1 infec-
tion. HIV-1 replication was assayed by FACS analysis 3 days
after infection by FACS analysis for the intracellular expres-
sion of HIV-1 CAp24. We measured 0.4 to 0.9% of HIV-1
CAp24 positive cells in unstimulated cells from different
donors challenged with HIV-1 alone. Conversely, when
exosome challenge preceded HIV-1 infection, a strong in-
crease in the number of HIV-1 Gag expressing cells was
observed (Figure 4A). The increase appeared slightly but re-
producibly less striking when cells were simultaneouslytreated with exosomes and HIV-1, whereas negligible ef-
fects were observed when HIV-1 infection preceded exo-
some challenge (Figure 4A). On the basis of these results,
the subsequent experiments were carried out by infecting
cells with HIV-1 6 hours after exosome treatment.
Similar to what we observed for TNF-α release, the ex-
tents of HIV-1 replication in CD4+ T lymphocytes corre-
lated with the exosome input (Figure 4B). Notably, the
treatment with 10 μM AZT led to a strong reduction of
HIV-1 CAp24-expressing CD4+ T lymphocytes (Figure 4C).
This result formally excluded that possible carry-over from
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Figure 2 Characterization of exosomes from supernatants of D10/Hut-78 and F12/Hut-78 cells. A. HIV-1 Gag contents and AchE activity
measured in fractions from 6-18% iodixanol gradients loaded with vesicles obtained by differential centrifugations of supernatants from D10/Hut-78
and F12/Hut-78 cells. The results are the mean values of duplicate conditions, and are representative of two independent experiments. B. Detection by
FACS of GM1 and CD63 on pools of AchE positive fractions from iodixanol gradients loaded with vesicles from F12/Hut-78 cells. Vesicles were bound
to aldehyde/sulfate latex beads and then labeled with both FITC-CTX-B and PE-conjugated anti-CD63 monoclonal antibody. Both FSC/SCC (on the left)
and fluorescence (on the right) dot plots are reported. The gate on the left panel includes both single and doublet beads considered for the fluorescence
analysis. The results are representative of three independent experiments carried out on vesicles from three iodixanol gradient preparations. C. Detection of
HIV-1 CAp24 (on the left) and Nef (on the right) by western blot analysis of both cells and exosomes from F12/Hut-78 and uninfected, parental Hut-78 cells.
On the left of each panel, arrows indicate the specific signals, while on the right molecular markers are given in kDa. Results are representative of two
(for CAp24 detection) and six (for Nef detection) independent experiments.
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http://www.retrovirology.com/content/11/1/46exosome- and/or virus-associated CAp24 interfered with
the results we obtained by FACS analysis, meanwhile indi-
cating that HIV-1 was indeed expressed in unstimulated
CD4+ T lymphocytes challenged with exosomes from F12/
Hut-78 cells.
Next, we were interested in establishing whether HIV-1
expressing CD4+ T lymphocytes released infectious virus. To
this end, CD4+ T cells were challenged with exosomes from
Hut-78 or F12/Hut-78 cells and then with HIV-1 in the pres-
ence or not of AZT. Three days later, CD4+ T cell cultures
were washed, and co-cultures with Rev-CEM reporter cells,
i.e., a cell line expressing GFP in the presence of both HIV-1
Tat and Rev products [34], were set up. After additional
3 days, the percentages of GFP-expressing Rev-CEM cells
were evaluated by FACS (Figure 4D). No significant increase
in the percentage of GFP+ cells was observed in Rev-CEM
from co-cultures with CD4+ T lymphocytes treated with
control exosomes, whereas a sharp increase was detectable
when the lymphocytes were treated with exosomes fromF12/Hut-78 cells. Such an increase was no more detectable
when challenged CD4+ T lymphocytes were cultured in the
presence of AZT until the addition of the reporter cells.
These results indicated that unstimulated CD4+ T lympho-
cytes release infectious virus when treated with exosomes
from F12/Hut-78 cells. In addition, the lack of infected Rev-
CEM cells in the co-cultures with CD4+ T lymphocytes chal-
lenged with control exosomes indicated that HIV-1 replicat-
ing in Rev-CEM cells did not originate from the viral input
used to infect the unstimulated CD4+ T lymphocytes.
We concluded that the exosome-dependent activation
of CD4+ T lymphocytes rendered them susceptible to
productive HIV-1 infection.
ADAM17 is involved in both activation and HIV-1 replication
in unstimulated CD4+ T lymphocytes treated with exosomes
from F12/Hut-78 cells
Next, we investigated the mechanism underlying the cell
activation in unstimulated CD4+ T lymphocytes targeted
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Figure 3 Unstimulated CD4+ T lymphocytes release IL-2 and TNF-α when treated with exosomes from F12/Hut-78 cells. A. Detection of
IL-2-producing cells. 2 × 105 unstimulated CD4+ T lymphocytes were challenged with 60 μU of exosomes from either Hut-78 or F12/Hut-78 cells,
or mock-challenged (Nil), and then incubated for 48 hours in ELISPOT microwells previously coated with an anti-IL-2 monoclonal antibody. Shown
are the mean number + SD of IL-2 spot forming units (SFU)/106 cells calculated from five independent experiments. *p < 0.05. B. Detection of
TNF-α on supernatants. 105 unstimulated CD4+ T lymphocytes were challenged with increasing amounts (i.e., from 15 to 60 μU) of exosomes
from Hut-78 or F12/Hut-78 cells, or mock-challenged (Nil). As control, cells were also treated with 2 μg/mL of PHA. After extensive washings, the
cells were seeded in complete medium, and supernatants were harvested 6 hours later. TNF-α contents were determined by ELISA. Shown are
the mean concentrations + SD as calculated from three independent experiments. Nd: not detectable. *p < 0.05.
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http://www.retrovirology.com/content/11/1/46by exosomes from F12/Hut-78 cells. It has been recently
reported that the expression of HIV-1 Nef leads to incorp-
oration of active ADAM17 into exosomes. Upon ingestion
of these exosomes, unstimulated CD4+ T lymphocytes re-
lease TNF-α as consequence of the cleavage of pro-TNF-α
driven by exosome-associated ADAM17 [35]. ADAM17
belongs to the family of ADAM (a disintegrin and metal-
loprotease) enzymes [36]. It is a multi-domain, transmem-
brane, Zn2+-dependent proteinase whose inactive form
presents a pro-domain which can be cleaved by furin in
trans-Golgi network. The most characterized function of
active ADAM17 is the cleavage of pro-TNF-α to its active
form. We asked whether exosome-associated ADAM17
was involved in the CD4+ T lymphocyte activation weobserved. To this aim, we first assayed the presence of
active ADAM17 in exosomes from F12/Hut-78 cells.
Western blot analysis highlighted the presence of active
ADAM17 in F12/Hut-78 cells but not in parental Hut-78
cells (Figure 5A). Consistently, active ADAM17 was found
in exosomes from F12/Hut-78 cells but not from unin-
fected cells (Figure 5B). Notably, inactive ADAM17 was
not found in exosomes.
To test a possible contribution of ADAM17 shuttled by
exosomes, we treated CD4+ T lymphocytes with TAPI-2,
i.e., a potent ADAM17 inhibitor [37]. We observed that
TAPI-2 inhibited the release of TNF-α from unstimulated
CD4+ T lymphocytes challenged with exosomes from F12/
Hut-78 cells (Figure 6A). Consistently, TAPI-2 also inhibited
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Figure 4 (See legend on next page.)
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Figure 4 HIV-1 replicates in unstimulated CD4+ T lymphocytes treated with exosomes from F12/Hut-78 cells. A. FACS analysis of
challenged lymphocytes. 105 CD4+ T lymphocytes were challenged with 60 μU of exosomes from F12/HIV-1 cells, and then infected with HIV-1.
Alternatively, exosomes and HIV-1 were added to cells at the same time, or cells were first infected and then challenged with the exosomes. As
control, cells were infected with or without PHA. Three days later, the cells were scored for the expression of HIV-1 Gag by FACS analysis. In the
upper panels, shown are the dot-plots from a representative experiment. Percentages of HIV-1 Gag positive cells are indicated. In the bottom
panel, shown are the fold increases of the percentages of HIV-1 CAp24-positive cells compared to cultures treated with HIV-1 alone. Shown are
the mean of fold increases + SD as calculated from five independent experiments with duplicates. *p < 0.05. B. Dose–response effect of exosomes.
Shown are the mean of fold increases + SD as calculated from three independent experiments with triplicates. *p < 0.05. C. Effects of AZT. Cultures were
run in the absence (Nil) or in the presence of 10 μM AZT. Shown are the mean of fold increases + SD as calculated from three independent experiments
with duplicates. *p < 0.05. D. Detection of infectious HIV-1. 105 CD4+ T lymphocytes were challenged with 60 μU of exosomes from either Hut-78 or
F12/Hut-78 cells, and then infected with HIV-1 with or without AZT. Three days later, co-cultures with Rev-CEM cells were undertaken. After additional 3
days, GFP positive Rev-CEM cells were scored by FACS. Shown are the mean of fold increases of GFP+ Rev-CEM cells from exosome-treated cells
compared to co-cultures with lymphocytes treated with HIV-1 alone, as calculated from two independent experiments with duplicates.
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http://www.retrovirology.com/content/11/1/46the viral replication in unstimulated CD4+ T lymphocytes
challenged with exosomes from F12/Hut-78 cells and then
infected with HIV-1 (Figure 6B). Taken together, these data
highlight the role that exosome-associated ADAM17 plays
in the activation and HIV-1 replication in CD4+ T lympho-
cytes treated with exosomes from F12/Hut-78 cells.
Both TNF-α neutralization and blocking TNF-α receptors-1
and −2 inhibit the HIV-1 replication in primary unstimulated
CD4+ T lymphocytes treated with exosomes from
F12/Hut-78 cells
Besides ADAM17, TAPI-2 inhibits other ADAMs, ACE
secretase, and other metalloproteinases. To ensure thatF
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then cultured for 3 days in the presence of anti-TNF-α
neutralizing antibodies. For control, cells challenged
with HIV-1 alone were treated with recombinant TNF-α
in the presence/absence of the anti-TNF-α antibodies.
We observed that anti-TNF-α antibodies totally abol-
ished HIV-1 replication in CD4+ T lymphocytes treated
with exosomes from F12/Hut-78 cells as well as in cells
treated with recombinant TNF-α, which, as expected,H
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Figure 6 The inhibition of ADAM17 activity impairs both TNF-α
release and HIV-1 replication in unstimulated CD4+ T
lymphocytes treated with exosomes from F12/Hut-78 cells.
A. Effect of TAPI-2 on TNF-α release. 105 unstimulated CD4+ T
lymphocytes were challenged with 60 μU of exosomes from either
Hut-78 or F12/Hut-78 cells, or, as control, treated with 2 μg/mL of PHA.
After extensive washings, the cells were cultured for 6 hours in the
presence or not (Nil) of the indicated concentrations of TAPI-2.
Thereafter, supernatants were harvested and titrated for the presence of
TNF-α. Shown are the mean + SD of TNF-α concentrations as calculated
from three independent experiments with duplicates. *p< 0.05. B. Effect
of TAPI-2 on HIV-1 replication. 105 unstimulated CD4+ T lymphocytes
were challenged with 60 μU of exosomes from either Hut-78 or F12/
Hut-78 cells, and then infected by HIV-1. As control, unstimulated cells
were challenged with HIV-1 alone, or in the presence of 2 μg/mL of
PHA. The cells were then left in culture for 3 days in the presence or not
(Nil) of the indicated concentrations of TAPI-2. Finally, the cells were
analyzed for HIV-1 expression by FACS analysis. The fold increases
of the percentages of HIV-1 CAp24-positive cells compared to
cultures treated with HIV-1 alone are reported. Shown are the
mean of fold increases + SD as calculated from three independent
experiments with duplicates. *p < 0.05.
Figure 7 TNF-α drives the HIV-1 replication in unstimulated
CD4+ T lymphocytes treated with exosomes from F12/Hut-78
cells. A. Neutralization of soluble TNF-α. 105 unstimulated CD4+ T
lymphocytes were challenged with 60 μU of exosomes from either
Hut-78 or F12/Hut-78 cells, and then infected with HIV-1. After
washings, the cells were cultured in the presence of anti-TNF-α
neutralizing antibodies or with unrelated IgGs. As control, unstimulated
CD4+ T lymphocytes were treated with the indicated doses of
recombinant TNF-α, infected by HIV-1, and then cultured in the
presence of anti-TNF-α neutralizing antibodies or IgGs. Three days
after challenges, the cells were analyzed for HIV-1 expression by FACS
analysis. The fold increases of the percentages of HIV-1 CAp24-positive
cells compared to cultures treated with HIV-1 alone are presented.
Shown are the mean of fold increases + SD as calculated from three
independent experiments with duplicates. *p < 0.05. B. Effects of the
block of TNFR1 and TNFR2. The same procedure described for panel A
was applied, except than unstimulated lymphocytes were incubated
with neutralizing anti-TNFR1 or -TNFR2 antibodies either alone or
in combination, or irrelevant isotype IgGs for 1 hour at 4°C before
exosome and HIV-1 challenges. Three days later, the cells were
analyzed for HIV-1 expression by FACS analysis. The fold increases
of the percentages of HIV-1 CAp24-positive cells compared to
lymphocytes treated with HIV-1 alone are presented. Shown are
the mean of fold increases as calculated from two independent
experiments with duplicates.
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ner (Figure 7A).
To further strengthen the role of TNF-α, experiments
with neutralizing antibodies against the TNF-α receptors(TNFR)-1 and 2, either alone or in combination, were per-
formed. According to what we observed with anti-TNF-α
antibodies, the treatment with anti-TNFR1 and –TNFR2
antibodies alone or in combination inhibited the HIV-
1 replication in unstimulated CD4+ T lymphocytes chal-
lenged with exosomes from F12/Hut-78 cells (Figure 7B).
This result suggests that the activation of both TNFR1- and
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HIV-1 replication in unstimulated CD4+ T lymphocytes.
Overall, these results supported the data we obtained
with TAPI-2, and are consistent with the idea that TNF-α
was the downstream effector of exosome-associated
ADAM17.
Unstimulated CD4+ T lymphocytes replicate HIV-1 when
targeted by exosomes released by cells expressing NefF12
Active ADAM17 was previously reported to be uploaded
in exosomes as consequence of the ectopic expression
of wild-type Nef in producer cells [35]. The upload of
active ADAM17 in exosomes from F12/Hut-78 cells
was suggestive of a key role of NefF12 in the induction of
HIV-1 susceptibility in CD4+ T lymphocytes. To investigate
this point, 293 T cells were transiently transfected with vec-
tors expressing NefF12 or, as control, NefG2A, i.e., a mutant
which is not expected to assemble the Nef-associated
kinase complex required for ADAM17 uploading in
exosomes [38]. This phenotype is the consequence of
the lack of the N-terminal myristoylation site which
dramatically decreases the efficiency of Nef association
with cell membranes. We noticed that NefF12, differently
to NefG2A, was incorporated into exosomes (Figure 8A).
Unstimulated CD4+ T lymphocytes were challenged with
equal amounts of exosomes derived from cells expressing
either NefF12 or NefG2A. As control, cells were treated with
exosomes derived from either mock-transfected cells or
F12/Hut-78 cells. Six hours later, the cells were infected
with HIV-1, and after additional 3 days, analyzed for HIV-
1 expression. HIV-1 replicated at similar extents in cell
cultures treated with exosomes from F12/Hut-78 cells or
NefF12-expressing cells, while no HIV-1 replication was
detectable in cells treated with control or NefG2A exo-
somes (Figure 8B).
These results indicate that the expression of NefF12 in
exosome-producing cells is sufficient to render un-
stimulated CD4+ T lymphocytes susceptible to HIV-1
infection.
Unstimulated CD4+ T lymphocytes become susceptible
to HIV-1 infection when co-cultivated with activated
CD4+ T lymphocytes infected by a NefF12-expressing,
non-producer HIV-1
Finally, we were interested in establishing whether NefF12
expressed in both viral and cellular contexts different from
F12/Hut-78 cells maintains its key role in inducing HIV-1
susceptibility on bystander CD4+ T lymphocytes. To this
end, PHA-activated primary CD4+ T lymphocytes were
infected by a NL4-3 HIV-1 strain where wt Nef was re-
placed by NefF12 [39], and which was pseudotyped with
the G protein from vesicular stomatitis virus (VSV-G). As
for F12/Hut-78 cells, cells expressing this HIV-1 strain do
not release viral particles, in the presence however of theexpression of a complete viral protein pattern [39]. Both
mock and infected cell cultures were put in the upper
chamber of trans-well plates where unstimulated CD4+ T
lymphocytes were seeded in the lower one, in the presence
or not of the exosome inhibitors GW4869 and Spiroepoxide.
After an overnight incubation, unstimulated CD4+ T lym-
phocytes were recovered from trans-well plates and in-
fected with HIV-1. Three days later, HIV-1 replication in
unstimulated cells was evaluated by FACS analysis. We
noticed that HIV-1 replicated in unstimulated CD4+ T
lymphocytes from co-cultures with cells infected with the
NL4-3/NefF12 HIV-1 strain but not mock infected cells
(Figure 9). The viral replication was no more detectable
when the co-cultures were carried out in the presence of
the exosome inhibitors (Figure 9).
These results add significance to what we previously
observed with 293 T transfected cells in terms of the key
role of NefF12 expression in the HIV-1 replication in by-
stander CD4+ T lymphocytes.
Discussion
Formal demonstration of the presence of grossly defect-
ive HIV-1 genomes in PBMCs of AIDS patients was
achieved in mid ‘90s [3]. Physical mapping of defective
genomes indicated that the frequency of deletions is pro-
portional to their proximity to the central part of the
viral genome [3]. Subsequent studies demonstrated the
presence of genetically damaged sequences in transcrip-
tionally active proviral HIV-1 [40]. Moreover, HAART
treatment further selects for mutated/deleted viral ge-
nomes in both PBMCs and rectal tissues [4,41]. The
identification of an in vitro cell system comprehensively
reproducing the events which in vivo lead to the forma-
tion of defective HIV-1 DNA is still an unmet challenge.
The functionally defective F12/HIV-1 genome [42] could
recapitulate some features of different defective HIV-1
species which in vivo remain transcriptionally active.
Our investigations started from the observation that
unstimulated CD4+ T lymphocytes became susceptible
to HIV-1 infection upon trans-well co-culture with F12/
Hut-78 cells. This experimental setting was useful to
avoid misinterpretations due to possible effects induced
by cell-to-cell contact. However, it is fairly conceivable
that it mirrors events occurring in free co-cultures and,
more important, in tissues most relevant for HIV repli-
cation, e.g., gut mucosa and lymph nodes.
Unstimulated CD4+ T lymphocytes challenged by exo-
somes from F12/Hut-78 cells released both IL-2 and
TNF-α. The fact that no IL-2 production was detectable
until 36–48 hours after exosome challenge (data not
shown) suggested that its release was consequence of
the cellular activation induced by an autocrine/paracrine
stimulus of TNF-α. The prompt release of TNF-α ap-
pears to be the key event leading to the activation of
Figure 8 HIV-1 replicates in unstimulated CD4+ T lymphocytes treated with exosomes from NefF12-expressing cells. A. Detection of Nef
in cells expressing either NefF12 or NefG2A, and in exosomes purified from the respective supernatants. Shown is the anti-Nef western blot analysis
of both cells and exosomes from either 293 T cells transiently transfected with vectors expressing NefF12 or NefG2A, or mock-transfected cells (Ctrl).
Signals from cellular Nef were normalized with β-actin detection, and anti-ICAM-1 analysis served to normalize exosome signals. On the left
of Nef-specific panels, arrows indicate the specific signals. On the right, molecular markers are given in kDa. Results are representative of two
independent experiments. B. HIV-1 replication in unstimulated CD4+ T lymphocytes treated with exosomes from cells expressing either NefF12 or
NefG2A. 10
5 unstimulated CD4+ T lymphocytes were challenged with 60 μU of exosomes from either F12/Hut-78 cells, 293 T cells transfected with
NefF12- or NefG2A-expressing vectors, or mock-transfected cells (Ctrl), and then infected with 50 ng of HIV-1. As control, unstimulated cells were
challenged with HIV-1 alone. Three days later, the cells were analyzed by FACS for HIV-1 expression. The fold increases of the percentages of
HIV-1 CAp24-positive cells compared to cultures treated with HIV-1 alone are reported. Shown are the mean of fold increases + SD as calculated
from three independent experiments with duplicates. *p < 0.05.
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somes from F12/Hut-78 cells.
It was reported that HIV-1 does not replicate in quies-
cent CD4+ T lymphocytes due to its inability to complete
retrotranscription and integration steps [33,43,44]. On the
other hand, TNF-α has manifold effects on HIV infection:
for instance, it activates resting CD4+ T lymphocytes
meanwhile stimulating TAK, i.e. a cell kinase required for
the Tat trans-activation [45]. It can also re-activate latent
HIV-1 through the action of its downstream effectors [46].
Our evidences that unstimulated CD4+ T lymphocytes be-
came susceptible to HIV-1 infection when the exosome-
mediated stimulus was applied before but not after HIV-1infection are highly reminiscent of previously published data
on resting CD4+ T lymphocytes stimulated with anti-CD3/
CD28 antibodies before or after HIV-1 challenge [33]. In this
experimental setting, a great increase of both fully retrotran-
scribed and integrated products was found in pre-stimulated
compared to post- and non-stimulated cells. On the basis of
these literature data, we hypothesize that the TNF-α released
upon exosome challenge helps the viral genome to complete
early replication events. Upon provirus integration, the acti-
vation of the downstream effectors of both TNF-α and IL-2
would contribute to foster HIV-1 transcription.
We found active ADAM17 in F12/Hut-78 cells and
exosomes released by them, but not in uninfected cells.
Figure 9 HIV-1 replicates in unstimulated CD4+ T lymphocytes co-cultured in trans-well plates with activated CD4+ T lymphocytes
expressing the non-producer NL4-3/NefF12 HIV-1 strain. CD4
+ T lymphocytes were activated by PHA and, 2 days later, either infected by
100 ng CAp24/106 cells of (VSV-G) NL4-3/NefF12 HIV-1, or mock infected. After 2 additional days, the infected cells were put in the upper chamber
of trans-well plates where unstimulated CD4+ T lymphocytes were seeded in the bottom chamber. After overnight co-culture in the presence or
not of GW4869 and Spiroepoxide, the unstimulated CD4+ T lymphocytes were recovered and infected by a T-tropic HIV-1 strain. As control, at the
same time untreated CD4+ T lymphocytes were infected by HIV-1. Three days later, the lymphocyte cultures were analyzed by FACS for the HIV-1
expression. A. CAp24 FACS analysis of PHA-activated CD4+ T lymphocytes infected with (VSV-G) NL4-3/NefF12 HIV-1 at the time of recovery of
unstimulated CD4+ T lymphocytes from trans-well chambers. The fluorescence plots are overlaid with those from untreated or treated uninfected
cells. B. Fold increases of the percentages of HIV-1 CAp24-positive unstimulated CD4+ T lymphocytes from the co-cultures 3 days after the
challenge with HIV-1. The HIV-1 positive percentages were compared to those measured in HIV-1 infected, untreated cells. Shown are the mean
of fold increases as calculated from two independent experiments with duplicates.
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inactive ADAM17 compared to the active form, only the
latter seemed to be uploaded in exosomes. The mechan-
ism of selective upload of active ADAM17 deserves fur-
ther investigations.
We cannot formally exclude that NefF12 delivered in
target cells by exosomes could contribute to the cell acti-
vation/HIV-1 replication in unstimulated lymphocytes.
However, the fact that NefF12 allele lacks many Nef signal-
ing functions [13,14] runs against this hypothesis. Most
important, the domain critical for ADAM17 activationand uploading into exosomes (i.e., the N-terminal 11–40
region) [35,38] is conversely well conserved in NefF12 [12].
Our results allow to propose a model where cells express-
ing defective HIV-1 genomes release ADAM17-loaded exo-
somes which, when ingested by bystander quiescent CD4+
T lymphocytes, can induce the cleavage of pre-stored pro-
TNF-α. The mature cytokine may act in an autocrine/
paracrine way by activating intracellular signals supporting
the progression of the life cycle of infectious HIV-1. Thus,
our results suggest that defective HIV-1 genomes which
are transcriptionally active could play a relevant role in
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Furthermore, they strengthen previous evidences about
the key role of TNF-α in HIV pathogenesis [47].
This mechanism would be of particular importance in
HAART-treated patients where defective HIV-1 genomes
accumulate in the presence of the block of the replication
of infectious virus. In this scenario, the activation of resting
CD4+ T lymphocytes induced by ADAM17-uploaded exo-
somes may foster the spread of replication-competent la-
tent HIV, which was estimated to represent 11.7% of
genomes [5], as well as the emergence of drug-resistant
HIV quasispecies and, when the therapy is interrupted,
infectious HIV. In addition, a sustained production of
exosomes inducing the release of active TNF-α could
contribute to the overall immune activation still present
in successfully HAART-treated patients.
Conclusions
Exosomes released by cells expressing a defective HIV-1
genome activate bystander, resting CD4+ T lymphocytes
and render them susceptible to HIV-1 infection. Exosome-
associated ADAM17 plays a key role in both cell activation
and HIV-1 replication observed in CD4+ T lymphocytes,
and TNF-α is its downstream effector. Overall, our data
reveal a so far neglected effect of defective but transcrip-
tionally active HIV-1 genomes on bystander lymphocytes
which could play a relevant role in the spread of HIV-1 in
infected persons.
Methods
Cell cultures and isolation
Hut-78, D10/Hut-78, F12/Hut-78 [11], and Rev-CEM cells
[34] were grown in RPMI medium plus 10% heat-
inactivated fetal calf serum (FCS). Human embryonic kid-
ney 293 T cells were grown in Dulbecco‘s modified Eagle’s
medium plus 10% heat-inactivated fetal calf serum (FCS).
CD4+ T lymphocytes were isolated from PBMCs of healthy
donors by negative selection using an immunomagnetic-
based kit (Miltenyi), and cultivated in RPMI medium plus
10% FCS. The cell cultures were checked for their purity
through FACS analysis for CD4, CD8, and CD14 markers.
Cell preparations having more than 3% of CD8+ cells
and /or 1% of CD14+ cells were discarded. For activation,
2 μg/mL of phytohemagglutinin (PHA) were added to
CD4+ T lymphocyte cultures. TAPI-2 was purchased
from Santa Cruz Biotechnology. Recombinant human
TNF-α was from R&D Systems. AZT was obtained
from NIH AIDS Research and Reference Reagent Program.
For anti-TNF-α neutralization experiments, 1 μg of either
anti-TNF-α neutralizing antibodies (polyclonal rabbit
antibodies, Fitzgerald Industries) or normal rabbit IgGs
was added to CD4+ T lymphocyte immediately after
exosome and HIV-1 challenges. The same amounts of
antibodies were then re-added after 24 hours of culture.For TNFR-blocking experiments, anti-TNFR1 clone #16085
and anti-TNFR2 clone #22210 neutralizing monoclonal
antibodies (both from R&D Systems) were used. CD4+ T
lymphocytes were incubated for 1 hour at 4°C with 1 μg
of the antibodies either alone or in combination or, as
control, with the same amount of isotype control IgGs,
and then challenged with exosomes and HIV-1. Antibodies
were then re-added 24 hours later.
Molecular clones, transfections, and HIV-1 infections
Preparations of T-tropic HIV-1 were obtained from the
supernatants of 293 T cells 48 hours after transfection
with the pNL4-3 HIV-1 molecular clone. The VSV-G
pseudotyped NL4-3/NefF12 HIV-1 strain [39] was ob-
tained by co-transfecting the HIV-1 molecular clone
with a pcDNA3.1 (Invitrogen)-based vector expressing
the VSV-G in a 5:1 molar ratio. Both NefF12 and NefG2A
alleles were cloned in the pcDNA3.1 vector after PCR
amplification from the HIV-1 molecular clones expressing
the respective Nef mutant [12,48]. Transfections were
performed using Lipofectamine 2000 (Invitrogen).
Supernatants were clarified and concentrated by ultra-
centrifugation on a 20% sucrose cushion as previously
described [49]. This method ensured that exosomes
from transfected cells were excluded from the vesicle
pellet [50]. Virus preparations were titrated in terms of
HIV-1 CAp24 content using quantitative enzyme-
linked immunosorbent assay (ELISA, Innogenetic). In-
fections with HIV-1 were carried out by spinoculation
at 400 × g for 30 min at room temperature (r.t.) using
500 ng CAp24 equivalent of HIV-1 for 106 cells.
Trans-well co-cultures
Trans-well co-cultures were carried out in 12-well plates
using Cell Culture Insert Falcon Membrane (25 mm
diameter, 0.4 μm pore size, Becton Dickinson). They
were set up by putting 106 F12/Hut-78 or parental Hut-
78 cells in the upper chamber, while 2 × 106 unstimu-
lated CD4+ T lymphocytes were seeded in the bottom
chamber. The co-cultures were then run overnight in
the presence or not of 1 μM of the inhibitors of exosome
release GW4869 (Sigma) and Spiroepoxide (Santa Cruz).
Then, CD4+ T lymphocytes were recovered and infected
with HIV-1, washed, and left in culture 3 days in the
presence or not of 10 μM AZT. Afterwards, lymphocytes
were analyzed by FACS for the HIV-1 expression through
the detection of intracytoplasmic HIV-1 CAp24.
Nanovesicle purification and challenge
Cell culture supernatants containing exosome-depleted
FCS were processed following already described methods
for exosome purification. In detail, supernatants were cen-
trifuged at 500 × g for 10 min and filtered with 0.22 μM
pore size. Then, the supernatants underwent differential
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10,000 × g for 30 min. Supernatants were then harvested
and ultracentrifuged at 70,000 × g for l h. The pelleted ves-
icles were resuspended in 1 × PBS, and ultracentrifuged
again at 70,000 × g for 1 h. Afterwards, the pellet was re-
suspended in 200 to 400 μL of 1 × PBS and, in some cases,
subjected to discontinuous iodixanol (Axis-Shield) gradi-
ent. It was performed essentially as described [51]. Briefly,
concentrated vesicles were ultracentrifuged at 200,000 × g
for 1.5 hours at 4°C in an SW41 Ti rotor (Beckman)
through a 6 to 18% iodixanol density gradient formed by
layering iodixanol in 1.2% increments. Then, 0.7 ml frac-
tions were collected starting from the top. In some in-
stances, half of each fraction was diluted with 2 volumes
of 0.9% sodium chloride and ultracentrifuged for 30 min
at 95,000 rpm in a TL-100 tabletop ultracentrifuge. Finally,
the pellet was resuspended in 50 μl of Tris–HCl pH 7.4
10 mM, NaCl 100 mM, EDTA 1 mM, 0.1% Triton X-100.
AchE activity assay
The vesicle-associated AchE activity was evaluated through
the Amplex Red kit (Molecular Probes) following the man-
ufacturer’s recommendations. The AchE activity was mea-
sured as mU/mL, where 1 mU is defined as the amount of
enzyme which hydrolyzes 1 pmole of acetylcholine to cho-
line and acetate per minute at pH 8.0 at 37°C.
FACS analysis of cells and nanovesicles
For the detection of intracytoplasmic HIV-1 CAp24, cells
were treated with trypsin for 15 min at 37°C. Then, they
were labeled using the KC57-RD anti-CAp24 monoclonal
antibody (Coulter) upon permeabilization with Cytofix/
Cytoperm solutions (BD Pharmingen) as previously de-
scribed [52].
Double staining of nanovesicles was performed by incu-
bating them with 5 μl of surfactant-free white aldehyde/
sulfate latex beads overnight at r.t. on a rotating plate.
The binding of exosomes with the beads was necessary for
both antibody labeling and FACS analysis. Afterwards,
nanovesicle-bead complexes were washed and incubated at
37°C for 2 hours with FITC-conjugated CTX-B. Then, the
samples were washed and incubated with PE-conjugated
anti-CD63 monoclonal antibody (BD Pharmingen) 1 h
at 37°C. Finally, the beads were washed, resuspended
in 1 × PBS-2% v/v formaldehyde, and FACS analyzed.
Western blot assay
Western blot analysis on cell lysates was performed by
washing cells twice with 1 × PBS (pH 7.4) and lysing
them for 20 min on ice with lysis buffer (20 mM HEPES
pH 7.9, 50 mM NaCl, 10 mM EDTA, 2 mM EGTA, 0.5%
nonionic detergent IGEPAL CA-630, 0.5 mM dithiothre-
itol, 20 mM sodium molybdate, 10 mM sodium orthova-
nadate, 100 mM sodium fluoride, 10 μg/mL leupeptin,0.5 mM phenylmethylsulfonyl fluoride). Whole cell ly-
sates were centrifuged at 6,000 × g for 10 min at 4°C.
The protein concentration of cell extracts was deter-
mined by the Lowry protein quantitation assay. Aliquots
of cell extracts containing 30 to 50 μg of total proteins
were resolved by 8-12% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and
transferred by electroblotting on a 0.45 μm pore size
nitrocellulose membrane (Amersham) overnight using a
Bio-Rad Trans-Blot. For western blot analysis of exo-
somes, they were lysed and analyzed as described for cell
lysates. For immunoassays, membranes were blocked
with 5% non-fat dry milk in PBS containing 0.1% Triton
X-100 for 1 hour at room temperature, then incubated
overnight at 4°C with specific antibodies diluted in PBS
containing 0.1% Triton X-100. The antibodies used in
immunoblots were: polyclonal rabbit anti-HIV-1 Gag
CAp24 #4250 (NIH AIDS Research and Reference Pro-
gram), sheep polyclonal anti-Nef ARP444 (a generous
gift from Dr. Mark Harris), rabbit polyclonal anti-
ADAM17 from Cell Signaling, monoclonal anti-ICAM-1
15.2 from Santa Cruz Biotech., monoclonal anti-CD63
from R&D Systems, and monoclonal anti-β-actin AC-74
(Sigma). Immune complexes were detected with horse-
radish peroxidase conjugated goat anti-rabbit or goat
anti-mouse antibodies (GE Healthcare) and enhanced
chemiluminescence reaction (Euroclone).IL-2 and TNF-α detection
The release from CD4+ T lymphocytes of IL-2 and TNF-
α was detected by ELISPOT and ELISA, respectively. For
IL-2, cells were treated with exosomes and then cultivated
for 48–72 hours in ELISPOT microwells (Millipore) previ-
ously coated with a monoclonal antibody against human
IL-2 (Mabtech). Afterwards, the cells were removed,
and a biotinylated antibody against human IL-2 was
added, followed by the addition of a streptavidin-alkaline
phosphatase. The plate was finally developed using BCIP/
NBT substrate (Sigma). Spot-forming cells were analyzed
and counted using an ELISPOT reader (Amplimedical
Bioline A-EL-VIS GmbH). The measurement of TNF-α
was performed through ELISA kits from Immunological
Sciences following the manufacturer’s recommendations.Statistical analysis
When appropriate, data are presented as mean + standard
deviation (SD). In some instances, the paired Student’s
t-Test was used and confirmed using the non-parametric
Wilcoxon rank sum test. P < 0.05 was considered
significant.
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